Combinations of drugs for the treatment of neoplastic disorders
AssigneeCombinatoRx, Incorporated
InventorsAlexis Borisy, Curtis Keith, Michael A. Foley, Brent R. Stockwell
Life of this patent
Estimating the term…
Abstract
The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts sufficient to treat the patient.
Claims13
A method for treating a patient having cancer, said method comprising administering to said patient:
- a) a first compound having the formula (I):
- 21
- or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of:
- 22
- R10 is selected from the group consisting of:
- 23
- each of R1, R3, R4, R5, R6, R7, R8, and R9 is, independently, H, OH, F, OCF3, or OCH3;
- and W is selected from the group consisting of:
- 24
- and
- b) a second compound having the formula (II):
- 25
- or a pharmaceutically acceptable salt thereof, wherein each of Y and Z is, independently, O or N;
- each of R11 and R12 is, independently, H, Cl, Br, OH, OCH3, OCF3, NO2, and NH2;
- n is an integer between 2 and 6, inclusive;
- and each of R13 and R14 is, independently, selected from the group consisting of:
- 26
- wherein said first and second compounds are administered simultaneously or within 14 days of each other in amounts sufficient to treat said patient.
A method for treating a patient having brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, or uterine cancer, said method comprising administering to said patient:
- a) a first compound having the formula (I):
- 27
- or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of:
- 28
- R10 is selected from the group consisting of:
- 29
- each of R1, R3, R4, R5, R6, R7, R8, and R9 is, independently, H, OH, F, OCF3, or OCH3;
- and W is selected from the group consisting of:
- 30
- and
- b) a second compound having the formula (II):
- 31
- or a pharmaceutically acceptable salt thereof, wherein each of Y and Z is, independently, O or N;
- each of R11 and R12 is, independently, H, Cl, Br, OH, OCH3, OCF3, NO2, and NH2;
- n is an integer between 2 and 6, inclusive;
- and each of R13 and R14 is, independently, selected from the group consisting of:
- 32
- wherein said first and second compounds are administered simultaneously or within 24 hours of each other in amounts sufficient to treat said patient.
Dependencies are inferred from the claim text.